Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

GeneDx Holdings Corp.

Filed: Jun 15, 2026CIK: 0001818331
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

GeneDx Holdings Corp. appointed Mark Gardner as President effective June 15, 2026, to oversee lab and commercial operations. This executive hire strengthens leadership with a genomics industry veteran from Quest Diagnostics.

Key Takeaways

Mark Gardner appointed President, reporting directly to CEO Katherine Stueland

Gardner brings significant experience from Quest Diagnostics as Senior Vice President of Molecular Genomics and Oncology

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 15, 2026
Item5.02
CategoryExecutive Change
CIK0001818331
Accession #wgs-20260615
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
executive hireleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings